News & Updates
Filter by Specialty:
Post-diagnosis use of risk stratification tools improves assessment of SMM patients
Despite only being validated for use at diagnosis, risk stratification scores, such as the Mayo-2018 and the International Myeloma Working Group (IMWG)-2020 criteria, appear to be viable for post-diagnosis use in patients with smouldering multiple myeloma (SMM), a recent study has found.
Post-diagnosis use of risk stratification tools improves assessment of SMM patients
29 Dec 2021
Interval between biopsy and RARP does not impact biochemical recurrence in prostate cancer
A prolonged gap between biopsy and robot-assisted radical prostatectomy (RARP) does not significantly influence the likelihood of biochemical recurrence (BCR) in prostate cancer patients, even in those who are considered high-risk, a recent Japan study has found.
Interval between biopsy and RARP does not impact biochemical recurrence in prostate cancer
28 Dec 2021
Venetoclax + chemo disappoints in double-hit lymphoma trial
In patients with double-hit lymphoma (DHL), the addition of the BCL2 inhibitor venetoclax to a chemoimmunotherapeutic regimen comprising DA-EPOCH-R* led to excess treatment-related mortality compared with DA-EPOCH-R alone, according to the initial results of the phase II/III Alliance A051701 trial.
Venetoclax + chemo disappoints in double-hit lymphoma trial
27 Dec 2021
Asian-derived polygenic risk scores boost risk stratification for breast cancer
Drawing from the largest available studies of Asian breast cancer patients, a recent Singapore study has developed polygenic risk scores (PRS) that can help improve the risk stratification of women of Asian ancestry.
Asian-derived polygenic risk scores boost risk stratification for breast cancer
27 Dec 2021
Sintilimab-IBI305-chemo improves PFS in EGFRm non-squamous NSCLC
The combination of the anti-PD-1 monoclonal antibody sintilimab with the bevacizumab biosimilar IBI305 and pemetrexed and cisplatin chemotherapy improved progression-free survival (PFS) in patients with EGFR*-mutated (EGFRm) non-squamous non-small-cell lung cancer (NSCLC), according to interim analysis results of the phase III ORIENT-31 trial from China.